Q-omics provides the consensus-scored C20orf85 profile across patient tissues and cancer cell-line models. C20orf85 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, C20orf85 is differentially expressed in 7, with the highest sampling consensus in LUAD. Additionally, C20orf85 RNA expression shows 8,330 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight KIRC, LUAD, and UCEC as cancer lineages where C20orf85 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C20orf85 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C20orf85 survival associations across molecular data types. C20orf85 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C20orf85 RNA expression–survival associations across cancer types. High C20orf85 expression shows unfavorable associations in KIRC, HNSC, BLCA and OV, but favorable associations in BRCA and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for C20orf85 RNA expression.
This table summarizes C20orf85 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for C20orf85. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C20orf85 shows lower tumor expression in LUAD, KIRC, LUSC, KICH and KIRP and higher tumor expression in BRCA. The LUAD box plot shows higher C20orf85 RNA expression in normal versus tumor tissue (log2 FC = −3.388, t-test p < 0.001).
This table shows molecular features associated with C20orf85 in patient tissues and cancer cell lines. In patient samples, C20orf85 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, C20orf85 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LUNG_SCLC.
